Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing